BRPI0909227B8 - uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) - Google Patents

uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)

Info

Publication number
BRPI0909227B8
BRPI0909227B8 BRPI0909227A BRPI0909227A BRPI0909227B8 BR PI0909227 B8 BRPI0909227 B8 BR PI0909227B8 BR PI0909227 A BRPI0909227 A BR PI0909227A BR PI0909227 A BRPI0909227 A BR PI0909227A BR PI0909227 B8 BRPI0909227 B8 BR PI0909227B8
Authority
BR
Brazil
Prior art keywords
antibody
vincristine
cyclophosphamide
doxorubicin
hodgkin
Prior art date
Application number
BRPI0909227A
Other languages
English (en)
Inventor
Dumontet Charles
Klein Christian
Herting Frank
Umana Pablo
Friess Thomas
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40872445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909227(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of BRPI0909227A2 publication Critical patent/BRPI0909227A2/pt
Publication of BRPI0909227B1 publication Critical patent/BRPI0909227B1/pt
Publication of BRPI0909227B8 publication Critical patent/BRPI0909227B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin. a presente invenção refere-se ao uso de um anticorpo anti cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) para a fabricação de um medicamento para o tratamento de câncer especialmente de cânceres expressando cd20 em combinação com um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida, vincristina e doxorubicina.
BRPI0909227A 2008-03-25 2009-03-23 uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) BRPI0909227B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08005554 2008-03-25
EP08005554.4 2008-03-25
EP08007172 2008-04-11
EP08007172.3 2008-04-11
PCT/EP2009/002111 WO2009118142A1 (en) 2008-03-25 2009-03-23 Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Publications (3)

Publication Number Publication Date
BRPI0909227A2 BRPI0909227A2 (pt) 2015-12-01
BRPI0909227B1 BRPI0909227B1 (pt) 2020-11-24
BRPI0909227B8 true BRPI0909227B8 (pt) 2021-05-25

Family

ID=40872445

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909227A BRPI0909227B8 (pt) 2008-03-25 2009-03-23 uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)

Country Status (31)

Country Link
US (6) US20090246197A1 (pt)
EP (1) EP2268310B1 (pt)
JP (3) JP5547709B2 (pt)
KR (1) KR101280716B1 (pt)
CN (2) CN107198772A (pt)
AR (1) AR072947A1 (pt)
AU (1) AU2009228616B2 (pt)
BR (1) BRPI0909227B8 (pt)
CA (1) CA2716884C (pt)
CL (1) CL2009000713A1 (pt)
CR (1) CR11687A (pt)
CY (1) CY1117984T1 (pt)
DK (1) DK2268310T3 (pt)
ES (1) ES2592312T3 (pt)
HR (1) HRP20161301T1 (pt)
HU (1) HUE028828T2 (pt)
IL (1) IL208018A (pt)
LT (1) LT2268310T (pt)
MA (1) MA32140B1 (pt)
MX (1) MX2010009647A (pt)
MY (1) MY163544A (pt)
NZ (1) NZ587284A (pt)
PE (1) PE20091821A1 (pt)
PL (1) PL2268310T3 (pt)
PT (1) PT2268310T (pt)
RS (1) RS55258B1 (pt)
RU (1) RU2589704C2 (pt)
SI (1) SI2268310T1 (pt)
TW (1) TWI500624B (pt)
WO (1) WO2009118142A1 (pt)
ZA (1) ZA201006190B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961563B2 (ja) 1991-01-29 1999-10-12 株式会社トーキン パルス発生用磁気ワイヤの製造方法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
KR101280716B1 (ko) * 2008-03-25 2013-07-01 로슈 글리카트 아게 비-호지킨 림프종의 치료를 위한, 시클로포스파미드, 빈크리스틴 및 독소루비신과 조합으로의 증가된 항체 의존성 세포 세포독성 (ａｄｃｃ) 을 갖는 유형 ⅱ 항-ｃｄ20 항체의 용도
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
JP2014507384A (ja) * 2010-12-16 2014-03-27 ロシュ グリクアート アーゲー Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法
CN110801454A (zh) * 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
BR112016013741A2 (pt) * 2013-12-17 2017-10-03 Genentech Inc Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
TW201733621A (zh) * 2015-12-10 2017-10-01 世代好公司 細胞穿透性之花青耦合抗體
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20240050562A1 (en) 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
MX2022006289A (es) * 2019-11-25 2022-06-29 Agensys Inc Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12.
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4433506A1 (en) 2021-11-16 2024-09-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU3657899A (en) * 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
KR20110017020A (ko) * 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (en) * 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
PT1692182E (pt) * 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR20080031001A (ko) * 2005-06-02 2008-04-07 아스트라제네카 아베 Ｃｄ20에 대한 항체 및 그의 용도
RU2482132C2 (ru) * 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
US20110243931A1 (en) * 2007-09-02 2011-10-06 Thomas Friess Combination therapy with type i and type ii anti-cd20 antibodies
KR101280716B1 (ko) * 2008-03-25 2013-07-01 로슈 글리카트 아게 비-호지킨 림프종의 치료를 위한, 시클로포스파미드, 빈크리스틴 및 독소루비신과 조합으로의 증가된 항체 의존성 세포 세포독성 (ａｄｃｃ) 을 갖는 유형 ⅱ 항-ｃｄ20 항체의 용도

Also Published As

Publication number Publication date
IL208018A (en) 2017-12-31
BRPI0909227B1 (pt) 2020-11-24
US20110177067A1 (en) 2011-07-21
AR072947A1 (es) 2010-10-06
BRPI0909227A2 (pt) 2015-12-01
RU2010143454A (ru) 2012-05-10
US20100310581A1 (en) 2010-12-09
JP5547709B2 (ja) 2014-07-16
AU2009228616A1 (en) 2009-10-01
US20120301459A1 (en) 2012-11-29
NZ587284A (en) 2012-05-25
CL2009000713A1 (es) 2010-04-09
JP2014101370A (ja) 2014-06-05
SI2268310T1 (sl) 2016-11-30
JP5912142B2 (ja) 2016-04-27
MX2010009647A (es) 2010-09-28
WO2009118142A1 (en) 2009-10-01
MA32140B1 (fr) 2011-03-01
TW200951141A (en) 2009-12-16
JP2016121183A (ja) 2016-07-07
IL208018A0 (en) 2010-12-30
PL2268310T3 (pl) 2017-08-31
ZA201006190B (en) 2018-11-28
JP2011515428A (ja) 2011-05-19
US20160000911A1 (en) 2016-01-07
JP6154039B2 (ja) 2017-06-28
KR101280716B1 (ko) 2013-07-01
TWI500624B (zh) 2015-09-21
AU2009228616B2 (en) 2014-07-24
US20090246197A1 (en) 2009-10-01
PE20091821A1 (es) 2009-11-25
CN107198772A (zh) 2017-09-26
EP2268310A1 (en) 2011-01-05
HUE028828T2 (en) 2017-01-30
RU2589704C2 (ru) 2016-07-10
ES2592312T3 (es) 2016-11-29
CY1117984T1 (el) 2017-05-17
DK2268310T3 (en) 2016-08-15
EP2268310B1 (en) 2016-07-20
CA2716884C (en) 2017-10-03
CN101983071A (zh) 2011-03-02
US20140065134A1 (en) 2014-03-06
PT2268310T (pt) 2016-08-23
MY163544A (en) 2017-09-29
CR11687A (es) 2011-01-10
RS55258B1 (sr) 2017-02-28
KR20100121525A (ko) 2010-11-17
LT2268310T (lt) 2016-09-26
CA2716884A1 (en) 2009-10-01
HRP20161301T1 (hr) 2016-11-18

Similar Documents

Publication Publication Date Title
MA32140B1 (fr) Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens
ATE526987T1 (de) Dr5-antikörper und deren verwendung
RU2016122232A (ru) Комбинированная терапия на основе антитела к cd20 и ингибитора втк
SI2992016T1 (en) Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
CL2012002012A1 (es) Anticuerpo anti-cd38 o fragmento de este, capaz de destruir una célula cd38+ por apoptosis, citotoxicidad celular adcc y citotoxicidad cdc; anticuerpo humanizado; polinucleótido, vector y célula huésped que lo codifican; conjugado del anticuerpo con un compuesto citotóxico; composición farmacéutica con dichos anticuerpos; uso de los anticuerpos para tratar cáncer o enfermedad autoinmune; método para diagnosticar cáncer.
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
HRP20192058T1 (hr) Kombinirane terapije s anti-cd38 antitijelima
AR071733A1 (es) Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
MX2009003774A (es) Anticuerpos para linfotoxina-alfa.
MX2020009919A (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
ATE459653T1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
AR073425A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
EA201692041A1 (ru) Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и циклофосфамид
BR112022008756A2 (pt) Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
MX392539B (es) Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
RU2014123781A (ru) Комбинированная терапия с применением антитела к cd20 и человеческого il-15
MX2009010271A (es) Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
WO2020176748A8 (en) Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF